Back
Repligen Corporation (RGEN)
Life Sciences Tools & ServicesRGEN · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$181.13
+0.47%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$0.86
ROE
2.5%
Gross margin
53.1%
Debt/Equity
0.33x
Revenue growth
14.8%
Repligen Corporation — company intelligence
Earnings surprises
Q2 2026$0.54 vs $0.46 est+18.0%
Q1 2026$0.48 vs $0.39 est+21.9%
Q4 2025$0.49 vs $0.45 est+9.3%
Q3 2025$0.46 vs $0.43 est+7.8%
Analyst consensus · 28 analysts
23 Buy5 Hold0 Sell
Updated Aug 3, 2026
Insider activity · 90 days
0 buys2 sellsnet -1,263 shares
Garland Jason KSell 530 · Jul 16, 2026
Garland Jason KSell 733 · Jun 25, 2026
Recent SEC filings
4 — Insider transaction reportAug 21, 2026
10-Q — Quarterly reportJul 29, 2026
8-K — Material event reportJul 28, 2026
Latest news
3 Hyped Up Stocks We Keep Off Our Radar — Yahoo · 4d ago
MRK/MRNA's Personalized Cancer Therapy Delivers First Phase III Win — Yahoo · 5d ago
RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos — Yahoo · 5d ago
Repligen (RGEN) Stock Could Be 1% Overvalued Despite Its 45% Run — Yahoo · 5d ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.